Jazz Pharmaceuticals PLC $JAZZ Position Lowered by Assetmark Inc.
Assetmark Inc. significantly cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 93.6% in the third quarter, selling 77,769 shares. Despite this reduction, several other institutional investors increased their holdings in JAZZ. The company has also seen substantial insider selling, with 84,398 shares worth $14.96 million sold by insiders in the last 90 days, though institutions still own 89.14% of the stock.
Jazz Pharmaceuticals PLC $JAZZ Position Boosted by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly increased its stake in Jazz Pharmaceuticals (NASDAQ:JAZZ) during the third quarter, adding 145,865 shares to now hold 1,867,159 shares valued at approximately $246.1 million. This increase occurred despite recent insider selling by company executives like CAO Patricia Carr and SVP Mary Elizabeth Henderson. Analysts maintain a "Moderate Buy" consensus rating for Jazz Pharmaceuticals, with several firms raising their price targets, indicating a positive outlook for the specialty pharmaceutical company.
65,470 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Aberdeen Group plc
Aberdeen Group plc initiated a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by purchasing 65,470 shares valued at approximately $8.63 million, representing about 0.11% of the company. Institutional ownership of Jazz Pharmaceuticals is high at 89.14%, and analysts generally hold a "Moderate Buy" rating with a consensus target price of $205.67. Insider activity, however, shows recent net selling of 84,398 shares worth around $14.96 million over the past three months.
Jazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso™ Brain Cancer Therapy
Jazz Pharmaceuticals plc (JAZZ) has received accelerated FDA approval for Modeyso™, a new brain cancer therapy. This approval marks a significant development in oncology, expanding treatment options for patients with this challenging disease. The company anticipates Modeyso will be available to patients soon.
Envestnet Asset Management Inc. Sells 10,744 Shares of Jazz Pharmaceuticals PLC $JAZZ
Envestnet Asset Management Inc. reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by selling 10,744 shares, now holding 102,181 shares valued at $13.47 million. While institutional ownership remains high, notable insider sales have occurred, including a significant transaction by Director Bruce C. Cozadd. Analysts currently rate JAZZ as a "Moderate Buy" with an average target price of $205.67.
Jazz Pharmaceuticals (JAZZ) to Release Quarterly Earnings on Tuesday
Jazz Pharmaceuticals (JAZZ) is scheduled to release its Q4 2025 earnings after market close on Tuesday, February 24, 2026, with analysts forecasting EPS of $6.49 and revenue of $1.166 billion. The company has experienced significant insider selling recently, totaling $15.56 million by directors Heather Mcsharry and Bruce Cozadd. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $205.67.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals plc announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 12, 2026. Audio webcasts of the fireside chats will be available on the company's investor relations website, with replays archived for 30 days. The biopharma company focuses on developing life-changing medicines for rare diseases and maintains a diverse portfolio for epilepsies, cancers, and sleep disorders.
Jazz Pharma to stream March investor conference talks
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced its participation in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference. The company will host fireside chats at both events, which will be accessible via audio webcasts and archived replays on its Investors website for 30 days. This provides an opportunity for investors to gain insights into Jazz Pharmaceuticals' strategy and performance.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz Pharmaceuticals (JAZZ) is projected to announce a year-over-year increase in earnings and revenue for the quarter ending December 2025. The company's Earnings ESP of +7.90%, combined with a Zacks Rank #3, suggests a high probability of an earnings beat when results are released on February 24. Investors are advised to consider other factors alongside these indicators for stock betting.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz Pharmaceuticals (JAZZ) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended December 2025. The company has a Zacks Earnings ESP of +7.90% and a Zacks Rank of #3, suggesting a strong likelihood of beating the consensus EPS estimate of $6.62 per share. Investors are advised to consider the Zacks Earnings ESP and Rank as indicators for potential earnings beats.
Renee Gala Outlines Jazz Pharmaceuticals Vision And Pipeline Priorities For Investors
Jazz Pharmaceuticals CEO Renee Gala has presented a refreshed long-term vision emphasizing growth and research focus, particularly on prioritizing the development pipeline. This strategic outline aims to guide future product development across neurology, oncology, and cannabinoid therapies. Investors are encouraged to watch how this vision aligns with upcoming financial guidance and impacts resource allocation, especially given the company's concentrated portfolio and elevated implied volatility in its stock.
Renee Gala Outlines Jazz Pharmaceuticals Vision And Pipeline Priorities For Investors
Jazz Pharmaceuticals CEO Renee Gala has presented a refreshed long-term vision emphasizing pipeline development and resource allocation in neurology and oncology. This strategic outline is crucial for investors as it details the company's future product development and patient impact beyond typical quarterly updates. The market is already showing heightened interest, with high implied volatility in options ahead of upcoming results, making Gala's clear vision important for investor confidence and assessing potential risks and rewards.
LSV Asset Management Sells 41,884 Shares of Jazz Pharmaceuticals PLC $JAZZ
LSV Asset Management reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by selling 41,884 shares in the third quarter, retaining 2,511,858 shares valued at approximately $331.1 million. Institutional investors collectively own 89.14% of the stock, while insiders hold 4.30%, with significant insider selling activity observed in the past three months. Analysts maintain a generally positive outlook, with a "Moderate Buy" consensus rating and an average target price of $205.67.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock?
The options market is showing high implied volatility for Jazz Pharmaceuticals (JAZZ), particularly for the Mar 20, 2026 $55.00 Put, suggesting expectations of a significant stock movement. Analysts currently rate Jazz Pharmaceuticals as a Zacks Rank #3 (Hold) and have recently increased earnings estimates for the current quarter, indicating a potential trading opportunity due to the combination of analyst sentiment and options activity.
Feb. 24: Jazz Pharma webcast to break down 2025 results
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced it will report its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, after the close of U.S. markets. Following the release, management will host a live webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results, provide a business update, and answer questions. Interested parties are encouraged to register in advance via the Investors section of the company's website.
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Jazz Pharmaceuticals plc announced it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after the close of U.S. financial markets. The company will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss these results and provide a business and financial update. Interested parties can register for the webcast through the Jazz Pharmaceuticals website.
Essex Investment Management Co. LLC Invests $2.70 Million in Jazz Pharmaceuticals PLC $JAZZ
Essex Investment Management Co. LLC has acquired a new stake of 20,463 shares, valued at approximately $2.70 million, in Jazz Pharmaceuticals PLC during the third quarter. The specialty pharmaceutical company, Jazz Pharmaceuticals, has a consensus "Moderate Buy" rating from analysts with an average price target of $205.67, despite recent insider stock sales totaling around $21.99 million. Institutional investors hold a significant 89.14% of the stock.
Jazz Pharmaceuticals (JAZZ) Valuation After HERIZON GEA Trial Upside And Planned 2026 sBLA Filing
Jazz Pharmaceuticals is receiving positive attention following strong HERIZON GEA trial results and plans for a 2026 sBLA filing for gastroesophageal adenocarcinoma therapies, leading to significant share price returns over the past 90 days and one year. Despite a year-to-date share price decline, the company is considered 22.3% undervalued by analysts, with a fair value estimate of $213.00, driven by anticipated new therapy approvals and global expansion. Investors are advised to consider potential pipeline risks and patent expiries alongside the growth prospects.
Renaissance Group LLC Sells 7,254 Shares of Jazz Pharmaceuticals PLC $JAZZ
Renaissance Group LLC reduced its stake in Jazz Pharmaceuticals PLC by 12.9%, selling 7,254 shares and holding 49,103 shares valued at approximately $6.47 million. Despite significant insider selling over the past three months, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $205.67. Several institutional investors, including Royal Bank of Canada and Goldman Sachs, increased their holdings in Jazz Pharmaceuticals during the same period.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of "Moderate Buy" by Brokerages
Eighteen analysts have given Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) a consensus recommendation of "Moderate Buy," with an average 1-year price target of $205.67. Insider transactions show significant share sales by director Bruce C. Cozadd and CAO Patricia Carr, totaling over $21.99 million in the last 90 days. The stock recently opened at $165.50, with a market capitalization of $10.06 billion, a negative P/E of -27.27, and a 1-year range of $95.49–$182.99.
How HERIZON-GEA’s First-Line GEA Data And sBLA Plan At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story
Jazz Pharmaceuticals recently announced positive data from its HERIZON-GEA trial and intends to submit a supplemental Biologics License Application for first-line gastroesophageal adenocarcinoma treatment in early 2026. This development significantly enhances the company's investment narrative by providing a clear near-term catalyst and broadening the potential market for its pipeline asset, zanidatamab. While addressing potential concerns regarding debt and execution risks, the news highlights the drug's practice-changing profile and its potential to influence broader investment perspectives.
Allianz Asset Management GmbH Purchases 30,537 Shares of Jazz Pharmaceuticals PLC $JAZZ
Allianz Asset Management GmbH increased its stake in Jazz Pharmaceuticals PLC by 9.4% in the third quarter of 2025, purchasing an additional 30,537 shares. This brings their total holdings to 355,940 shares, valued at approximately $46.9 million. Despite insider selling, analysts maintain a "Moderate Buy" rating for Jazz Pharmaceuticals, with a consensus target price of $205.67.
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial
Truist Securities has increased its price target for Jazz Pharmaceuticals (JAZZ) to $230 from $220, maintaining a Buy rating. This adjustment follows positive results from the HERIZON-GEA trial, leading Truist to revise its Ziihera estimations higher. Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application in early 2026 for a broad label in first-line gastroesophageal adenocarcinoma, with strong commercial adoption anticipated post-clearance.
Strs Ohio Sells 14,393 Shares of Jazz Pharmaceuticals PLC $JAZZ
STRS Ohio significantly reduced its stake in Jazz Pharmaceuticals PLC, selling 91.2% of its holdings, totaling 14,393 shares, in the third quarter. This comes amidst insider selling by company executives and a generally positive "Moderate Buy" consensus from analysts with an average price target of $205.67. Several other institutional investors, however, increased their positions in JAZZ during the same period.
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial
Truist Securities has increased its price target for Jazz Pharmaceuticals (JAZZ) to $230 from $220, maintaining a Buy rating. This adjustment follows positive results from the HERIZON-GEA trial, leading Truist to revise its Ziihera estimations upwards. Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application in the first half of 2026 for its treatment of first-line gastroesophageal adenocarcinoma.
Jazz Pharmaceuticals plc (JAZZ): Investor Outlook with a 32% Potential Upside and Strong Buy Ratings
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) presents a compelling investment opportunity in the biotech sector, highlighted by its robust product pipeline and attractive valuation metrics. Analysts have issued 15 buy ratings and one hold rating, with an average target price suggesting a 32.15% potential upside. Despite negative EPS and ROE, the company's strong free cash flow and focus on R&D for promising treatments like Zanidatamab and JZP441 underpin its long-term growth strategy.
Is Jazz Pharmaceuticals (JAZZ) Offering Opportunity After A 32% One Year Share Price Gain
Jazz Pharmaceuticals (JAZZ) has seen a 32.3% share price gain over the past year, but recent returns have been mixed. Simply Wall St's valuation models, including a Discounted Cash Flow (DCF) analysis and Price/Sales (P/S) ratio comparison, suggest the stock is significantly undervalued, with a potential intrinsic discount of 78.8% on a DCF basis. The article encourages investors to consider these valuations alongside their own narratives about the company's future.
These 4 Measures Indicate That Jazz Pharmaceuticals (NASDAQ:JAZZ) Is Using Debt Reasonably Well
Jazz Pharmaceuticals (NASDAQ:JAZZ) is managing its debt reasonably well despite a significant amount of liabilities. The company reduced its debt to US$5.36 billion by September 2025 and has US$2.05 billion in cash, resulting in net debt of US$3.32 billion. While its net debt to EBITDA ratio is 2.1x and interest cover is 4.6x, indicating some impact from debt costs, strong free cash flow generation (more than EBIT) suggests good debt repayment capacity.
Mitsubishi UFJ Trust & Banking Corp Raises Stake in Jazz Pharmaceuticals PLC $JAZZ
Mitsubishi UFJ Trust & Banking Corp significantly increased its stake in Jazz Pharmaceuticals PLC by 156.2% in the third quarter, bringing its total holdings to 50,869 shares. Despite this institutional buying, company insiders have been actively selling shares, with Director Bruce C. Cozadd and others disposing of a substantial amount. Wall Street analysts generally hold a "Moderate Buy" rating for Jazz Pharmaceuticals, with several firms recently raising their price targets for the stock.
Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Great Lakes Advisors LLC
Great Lakes Advisors LLC significantly increased its stake in Jazz Pharmaceuticals (NASDAQ:JAZZ) during Q3, purchasing 15,962 additional shares to hold a total of 64,962 shares worth around $8.56 million. Analysts have become more optimistic about the company, with various firms raising their price targets, leading to an average price target of $205.67 and a "Moderate Buy" consensus rating. Despite this, company insiders were net sellers in the last quarter, offloading 123,791 shares valued at about $21.99 million.
Lewy Body Dementia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt
The DelveInsight report provides an in-depth analysis of the Lewy Body Dementia (LBD) pipeline in 2025, detailing clinical trials, therapies, mechanisms of action, and key companies involved. It highlights that despite LBD's prevalence, treatments to halt or slow its progression are still emerging, with several promising drug candidates in various clinical phases. The report emphasizes the ongoing R&D efforts by companies like Eisai, EIP Pharma, and Cognition Therapeutics to address this unmet medical need.
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?
Despite significant financial success with its narcolepsy drug Wakix, including rapidly rising sales and profits, Harmony Biosciences' stock price has remained largely flat since its IPO. This discrepancy is attributed to concerns over the patent cliff for Wakix in 2030, a damaging short-seller report in 2023 alleging "sham patents" and "scam clinical trials," and strong competition from companies like Jazz Pharmaceuticals. Shareholder lawsuits further contribute to the bearish sentiment, overshadowing the company's impressive financial performance.
How Boehringer Ingelheim Oncology Collaboration Could Shape Jazz Pharmaceuticals' (JAZZ) Dual HER2 Strategy
Jazz Pharmaceuticals has announced a collaboration with Boehringer Ingelheim to test a combination of zongertinib and zanidatamab for HER2-positive breast cancer, potentially broadening future treatment options. While this partnership is a positive for Jazz's oncology pipeline, the company's investment narrative still largely depends on managing high debt, a leadership transition, and converting its late-stage portfolio into consistent profitability. The market currently prices in execution risk, ongoing losses, and insider selling, with a wide range of fair value estimates reflecting differing investor confidence.
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After New Boehringer Ingelheim Oncology Collaboration
Jazz Pharmaceuticals' recent oncology collaboration with Boehringer Ingelheim has brought renewed investor attention to the company, resulting in significant short-term stock momentum. Despite trading at a discount to the average analyst target, the company's valuation narrative suggests it is undervalued at $171, with a fair value pegged at $213 driven by R&D investments and international expansions. However, potential risks include looming patent expiries and high debt levels.
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After New Boehringer Ingelheim Oncology Collaboration
Jazz Pharmaceuticals' stock is gaining attention due to a new oncology collaboration with Boehringer Ingelheim, pairing zongertinib with zanidatamab for HER2-positive breast cancer. The company is currently trading at US$171, which is below the average analyst target of US$216.44 and a fair value estimate of $213, suggesting it may be undervalued. However, potential risks include looming patent expiries in its oxybate franchise and high debt levels.
Lmcg Investments LLC Trims Stake in Jazz Pharmaceuticals PLC $JAZZ
Lmcg Investments LLC decreased its stake in Jazz Pharmaceuticals PLC by 71.4% in the third quarter, selling 39,716 shares and retaining 15,925 shares valued at $2.10 million. Despite this, Wall Street analysts maintain a "Moderate Buy" rating for Jazz Pharmaceuticals with an average target price of $205.67. Insider transactions have seen 123,791 shares sold in the last 90 days, though institutional investors and hedge funds collectively own 89.14% of the company's stock.
New York State Teachers Retirement System Sells 9,223 Shares of Jazz Pharmaceuticals PLC $JAZZ
The New York State Teachers Retirement System has reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by 20.9% in the third quarter, selling 9,223 shares and now holding 34,854 shares valued at approximately $4.59 million. This comes amid significant insider selling, with corporate insiders divesting 123,791 shares totaling about $21.99 million over the past three months. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $205.67.
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization?
Jazz Pharmaceuticals (JAZZ) is strategically evolving its oncology focus through a new clinical collaboration with Boehringer Ingelheim for a HER2-positive breast cancer treatment and the sale of an FDA priority review voucher for $200 million. These actions aim to broaden the application of its HER2 antibody zanidatamab and monetize regulatory assets, providing cash for R&D and commercialization. The company faces ongoing challenges from patent expirations and debt but is working to boost its oncology pipeline versatility.
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization?
Jazz Pharmaceuticals (JAZZ) is strategically evolving its oncology focus through a new clinical collaboration with Boehringer Ingelheim for a HER2-positive breast cancer treatment and the monetization of an FDA priority review voucher for $200 million. These actions aim to expand zanidatamab's reach and fund R&D, although the company still faces challenges including debt and potential erosion of existing drug revenues. Investors are encouraged to consider diverse fair value estimates and the company's full financial health before making investment decisions.
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Jazz Pharmaceuticals has entered into a licensing agreement with Saniona for its epilepsy drug candidate, tesofensine. The deal is valued at up to $1 billion, including an upfront payment to Saniona. This partnership aims to develop and commercialize tesofensine globally, excluding certain territories.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of "Moderate Buy" by Brokerages
Seventeen brokerages have given Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) an average rating of "Moderate Buy," with an average 1-year price target of $205.67, indicating a 25% potential upside. Despite this positive analyst outlook, significant insider selling occurred in the last quarter, with 123,791 shares valued at $21.99 million sold. Institutional investors hold a substantial 89.14% of the company's stock, though there have been both increases and decreases in their positions.
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Jazz Pharmaceuticals has entered into an exclusive global licensing agreement with Saniona for their investigational epilepsy drug, SAN711. The deal could be worth over $1 billion for Saniona, including an upfront payment of $50 million. SAN711 is a first-in-class GABAA receptor modulator with potential for treating rare neurological disorders, and Jazz Pharmaceuticals plans to advance it into clinical development.
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum
Jazz Pharmaceuticals (JAZZ) has experienced recent positive share price momentum, with a 0.2% daily move and a 6.8% gain over the past week, bringing its valuation into focus. Analysts estimate a fair value of US$213 per share, suggesting the stock is currently undervalued, driven by expectations of strong long-term revenue growth and the potential of its oncology drug, Ziihera. However, potential risks like patent expirations and slower-than-expected new product ramps should also be considered.
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum
Jazz Pharmaceuticals (JAZZ) has shown recent positive momentum with a 6.8% gain over the past week and a 39.6% one-year return. Analysts consider the stock 19.6% undervalued, with a fair value pegged at US$213 per share due to stronger long-term revenue growth expectations. However, potential risks include patent expiries on its oxybate franchise and slower-than-expected ramps for new oncology and sleep launches.
JAZZ - Jazz Pharmaceuticals Plc Latest Stock News & Market Updates
This page provides the latest news and updates for Jazz Pharmaceuticals Plc (JAZZ), focusing on its activities in neuroscience and oncology. It covers clinical trial results, regulatory milestones for drugs like Epidiolex/Epidiolex, Xywav, Ziihera, and Modeyso, and corporate announcements. The content highlights significant advancements in areas such as sleep disorders, rare epilepsies, HER2-driven cancers, and aggressive brain tumors, offering a centralized resource for investors, clinicians, and patients.
Jazz Pharmaceuticals Soars with Promising HERIZON-GEA-01 Results
Jazz Pharmaceuticals' stock (NASDAQ: JAZZ) has risen by 5.93% following positive results from its HERIZON-GEA-01 trial and FDA designations for its drug Ziihera. The drug, targeting gastroesophageal adenocarcinoma, is expected to significantly impact treatment protocols and market share, leading to increased investor confidence and upward revisions in analyst price targets. Strategic leadership appointments, such as Thomas Riga as Chief Business Officer, further bolster optimism for the company's future growth trajectory.
Jazz Pharmaceuticals PLC $JAZZ Holdings Lessened by Polaris Capital Management LLC
Polaris Capital Management LLC reduced its stake in Jazz Pharmaceuticals PLC by 19% in the third quarter of last year, selling 120,694 shares and making the stock its fifth-largest holding. Despite this reduction, other institutional investors significantly increased their holdings, with institutions now owning 89.14% of the company's stock. Wall Street analysts maintain a "Moderate Buy" consensus rating for Jazz Pharmaceuticals, with a target price of $205.67.
JAZZ: Refined rare disease focus, strong 2025 results, and new launches drive future growth
Jazz Pharmaceuticals (JAZZ) has outlined a refined rare disease strategy, forecasting strong financial results for 2025. The company's future growth is expected to be driven by promising zanidatamab data and successful product launches like Modeyso and Zepzelca, with multiple franchises potentially exceeding $1 billion. Strategic acquisitions and robust R&D further solidify its position for sustained expansion.
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital
RBC Capital has reaffirmed its Outperform rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) with a price target of $194.00, citing that the market's reaction to recent zanidatamab data "misses the broader point" of the drug's effectiveness and commercial potential. Despite a recent stock price dip, the firm maintains its outlook for over $900 million in peak U.S. sales for zanidatamab in GEA, with the company showing strong momentum and positive developments in other drug trials. Other analysts like Piper Sandler and BofA Securities have also raised price targets following positive HERIZON-GEA-01 study results, though UBS downgraded the stock to Neutral.
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Boehringer Ingelheim has announced a clinical collaboration with Jazz Pharmaceuticals to develop a novel combination therapy for HER2-positive breast cancer patients. This collaboration will involve evaluating Boehringer’s zongertinib and Jazz’s zanidatamab in a Phase 1b cohort of Boehringer’s Beamion-BCGC1 trial. The goal is to improve outcomes for patients with this aggressive breast cancer subtype by combining two distinct HER2-targeted approaches.
